Furosemide Dose, IV Rate & Safety Guide

Drug Doses & Preparation | Complete professional monograph and note sheet

Furosemide is a potent loop diuretic used when rapid or reliable diuresis is required. Dose and response vary substantially with indication, renal function, prior diuretic exposure and haemodynamic status; treatment must therefore be individualised and clinically monitored.

Quick note sheet

Common injection concentration: 10 mg/mL (for example, 20 mg/2 mL).
Adult oedema—label starting dose: 20–40 mg IV or IM; repeat or titrate only according to response and the product label.
Paediatric oedema—label starting dose: 1 mg/kg IV or IM, administered slowly; subsequent increases require clinical reassessment.
Rate warning: rapid injection and excessive exposure increase ototoxicity risk. Follow the exact product label; where a rate is specified for high-dose parenteral therapy, do not exceed 4 mg/min.
Key monitoring: fluid balance, blood pressure, renal function, sodium, potassium, magnesium, calcium and hearing risk.

Lasix furosemide injection 20 mg per 2 mL ampoules by Sanofi Aventis, representative India-market example — India-market injectable example: Lasix 20 mg/2 mL (10 mg/mL), Sanofi Aventis. Image source: Saintroy product listing. Representative market example only; not an endorsement. Availability, pack and manufacturer information may change—verify the current Indian product label.

Clinical role and indications

Injectable furosemide is used for oedema associated with conditions such as heart failure, hepatic cirrhosis and renal disease when parenteral treatment is appropriate. Some labels also include adjunctive treatment of acute pulmonary oedema. It treats fluid overload; it does not correct the underlying cause.

Marketed formulations and strengths

Form	Common strength	Practical note
Injection ampoule/vial	10 mg/mL; commonly 20 mg/2 mL	Confirm concentration every time; presentations vary.
Oral tablet	20 mg, 40 mg and other market-dependent strengths	Bioavailability and switching require clinical judgement.
Oral solution	Market-dependent	Verify mg/mL, measuring device and excipients.

Verified adult dosing

Situation	Official-label starting regimen	Safety points
Oedema requiring parenteral therapy	20–40 mg IV or IM initially. Further dosing is based on response and label instructions.	Assess volume status, blood pressure, urine output, renal function and electrolytes before escalation.
Acute pulmonary oedema	Some US labels describe 40 mg IV slowly, with a further 80 mg after one hour if response is inadequate.	Use only in a monitored acute-care setting and follow the locally approved label/protocol.

Clinical caution: Do not convert these starting doses into an automatic repeat schedule. Patients with chronic kidney disease or prior loop-diuretic exposure may respond differently, while frail or volume-depleted patients may be harmed by routine escalation.

Verified paediatric dosing

For oedema, the US prescribing information gives an initial parenteral dose of 1 mg/kg IV or IM, administered slowly. If clinically necessary, the dose may be increased by 1 mg/kg no sooner than two hours after the preceding dose; doses above 6 mg/kg are not recommended in that label. Neonates, premature infants and children with renal or cardiac disease require specialist protocols because exposure, nephrocalcinosis risk and monitoring needs differ.

Educational calculation example

A 20-kg child is prescribed 1 mg/kg:

Dose = 20 kg × 1 mg/kg = 20 mg. If the verified ampoule concentration is 10 mg/mL, volume = 20 mg ÷ 10 mg/mL = 2 mL.

This is a calculation demonstration, not a prescription. Independently verify weight, indication, maximum dose, concentration, route and institutional paediatric policy.

Preparation, route and administration

Confirm the order, indication, patient weight where relevant, allergies, renal function, electrolytes, fluid status and current diuretics.
Read the ampoule/vial label and verify total milligrams and mg/mL. Do not identify strength by ampoule appearance.
Inspect the solution and container. Do not use particulate, discoloured, damaged or expired product.
Calculate and independently check the required volume.
Administer by the ordered route. For IV use, give slowly at the product-specific rate. Avoid rapid bolus administration.
If dilution or continuous infusion is required, use only a diluent, final concentration, container and beyond-use time supported by the actual product label, pharmacy data and local protocol.
Document dose, route, time, response, urine output and relevant observations.

Rate example

If a protocol limits the rate to 4 mg/min, a 40-mg dose requires at least 10 minutes (40 ÷ 4). A slower rate may be required by the product label or patient factors. Never use this arithmetic to override a stricter local instruction.

Storage, stability and compatibility

Store exactly as stated on the manufacturer’s pack, protect from conditions specified in the label and keep ampoules in their original packaging until use. Furosemide solutions are alkaline and may precipitate when mixed with acidic solutions. Do not mix with another medicine in the same syringe or line unless compatibility has been confirmed by an authoritative compatibility reference or pharmacy. Do not assign a generic beyond-use time to a diluted solution; product, concentration, diluent, container and aseptic conditions all matter.

Renal and hepatic considerations

Renal impairment may reduce diuretic response and prompt specialist titration, but rising creatinine can also signal hypovolaemia or haemodynamic deterioration. In severe progressive renal disease, marked azotaemia/oliguria or worsening laboratory values require reassessment and may require discontinuation. In cirrhosis, excessive diuresis can precipitate electrolyte disturbance and hepatic encephalopathy; initiate and monitor carefully, often in hospital.

Pregnancy and lactation

Use in pregnancy only when the expected benefit justifies fetal risk and maternal/fetal monitoring is available; diuretics are not routine treatment for physiological pregnancy oedema. Furosemide is present in human milk and intense diuresis may impair lactation. Decide with the treating clinician whether to continue breastfeeding or the medicine, considering dose, indication and infant risk.

Contraindications, major interactions and precautions

Contraindication: anuria and hypersensitivity to furosemide or formulation components, subject to the specific label.
Major risks: profound diuresis, dehydration, hypotension, electrolyte depletion, renal dysfunction and ototoxicity.
Important interactions: other ototoxic medicines (including aminoglycosides), lithium, NSAIDs, nephrotoxic medicines, antihypertensives and drugs affected by potassium disturbance. Review the complete medication list.

Adverse effects

Common/clinically expected: increased urination, dizziness, hypotension, dehydration and electrolyte abnormalities. Serious: severe volume depletion, arrhythmia related to electrolyte loss, acute kidney injury, hearing impairment/tinnitus, pancreatitis, severe skin reaction and blood dyscrasia. Urgent assessment is required for collapse, marked hypotension, oliguria, arrhythmia symptoms, acute hearing change or severe rash.

Monitoring checklist

Indication, weight and volume status
Blood pressure and clinical perfusion
Intake, urine output and daily weight when appropriate
Serum sodium, potassium, magnesium, calcium, bicarbonate, urea and creatinine
Glucose and uric acid when clinically relevant
Hearing symptoms, especially with high dose, rapid IV administration, renal impairment or other ototoxic drugs
Therapeutic response and need for each further dose

Medication-error and concentration warnings

Confusing mg with mL can cause a tenfold error—write both dose and concentration.
Do not assume every ampoule is 10 mg/mL.
Do not administer rapidly because the volume is small.
Check concurrent fluids and other diuretics to prevent unintended cumulative treatment.

Mandatory safety check: Verify the actual product label, concentration and local hospital protocol before preparation or administration. This monograph is educational and does not replace prescribing information, antimicrobial-stewardship advice or patient-specific clinical judgement.

What is known

Official labels support parenteral furosemide for selected oedematous states and provide starting doses and key safety warnings. Response is highly patient-specific, making clinical reassessment and laboratory monitoring essential.

Limitations and uncertainties

Regimens vary by indication, country, product and hospital protocol. This guide does not cover neonatal specialist dosing, continuous high-dose infusions, renal-replacement therapy or disease-specific escalation pathways. Indian brands and authorised indications may differ from the cited US label.

Furosemide: Complete Adult, Paediatric, IV Dose and Administration Guide